ABG
CYTK icon

Ally Bridge Group’s Cytokinetics CYTK Stock Holding History

Ally Bridge Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-223,382
Closed -$6.58M – 25
2023
Q3 		$6.58M Hold
223,382
– – 7.72% 6
2023
Q2 		$7.29M Hold
223,382
– – 8.83% 4
2023
Q1 		$7.86M Buy
+223,382
New +$9.11M 10.3% 4

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ally Bridge Group's CYTK Position: Q4 2023 in Review

Ally Bridge Group sold out of Cytokinetics (CYTK) in Q4 2023, closing a stake of 223,382 shares — an estimated $6.58M sold.

Ally Bridge Group first reported a position in CYTK in Q1 2023 and held it in 3 quarters. The position peaked at $7.86M in Q1 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2023.

  • Ally Bridge Group reported no remaining Cytokinetics position as of Q4 2023 after selling out during the quarter.
  • Ally Bridge Group sold 223,382 Cytokinetics shares in Q4 2023, an estimated $6.58M.
  • Ally Bridge Group first reported a position in Cytokinetics in Q1 2023 and held it in 3 quarters.
  • Ally Bridge Group's Cytokinetics position peaked at $7.86M in Q1 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2023.

Based on Ally Bridge Group's 13F filing for Q4 2023, filed 14 Feb 2024.